J Clin Invest. 2014 May;124(5):1891-3. doi: 10.1172/JCI75798. Epub 2014 Apr 17.
Three years ago, two research groups independently identified a previously undescribed T cell cosignaling molecule; one referred to it as V-domain Ig suppressor of T cell activation (VISTA), and the other used the term programmed death-1 homolog (PD-1H). Recombinant and ectopically expressed PD-1H functions as a coinhibitory ligand for T cell responses. However, the function of endogenous PD-1H is not clear. In this issue of the JCI, Flies and colleagues demonstrate that endogenous PD-1H on both T cells and APCs serves as a coinhibitory molecule for T cell activation and provide further support for targeting PD-1H as a therapeutic strategy for transplantation and cancers.
三年前，两个研究小组独立鉴定出一种以前未被描述的 T 细胞共刺激分子；一个称其为 V 结构域 Ig 抑制 T 细胞活化（VISTA），另一个则使用程序性死亡-1 同源物（PD-1H）的术语。重组和异位表达的 PD-1H 作为 T 细胞反应的共抑制配体发挥作用。然而，内源性 PD-1H 的功能尚不清楚。在本期 JCI 中，Flies 及其同事证明，T 细胞和 APC 上的内源性 PD-1H 均可作为 T 细胞活化的共抑制分子，并为将 PD-1H 作为移植和癌症的治疗策略提供了进一步的支持。
